Mount Sinai Dermatology

01/16/2026

A new JAAD Case Report by Dr. Jordan Talia with recent residency graduate Dr. Deep Pne, her disease remained steroid dependent with rapid flares on taper. Following confirmation of oral lichen planus through careful clinicopathologic correlation, initiation of ritlecitinib led to rapid symptomatic improvement within forty-eight hours, steroid discontinuation within two weeks, and durable disease control 🔥💊.atel, highlights a novel therapeutic approach for severe erosive oral lichen planus using the JAK3 and TEC kinase inhibitor ritlecitinib 🧬👄. They describe a woman with an eighteen-month history of painful, refractory oral erosions and desquamative gingivitis that significantly impaired eating and quality of life. Despite prolonged treatment with topical therapies, doxycycline, and chronic low-dose predniso

📚https://bit.ly/3MSu1mx

This case is important for Dermatology because erosive oral lichen planus remains one of the most challenging inflammatory mucosal diseases to manage, often requiring long-term systemic immunosuppression with significant toxicity ⚠️. The dramatic and reproducible response to ritlecitinib supports a central role for JAK-mediated signaling in oral lichen planus pathogenesis and highlights JAK3 inhibition as a promising targeted strategy 🎯. Unlike broader immunosuppressants, selective pathway inhibition may offer more durable control with an improved safety profile, particularly for patients with steroid-dependent or refractory disease. Given the known risk of malignant transformation in oral lichen planus, achieving sustained inflammation control is not only symptomatic relief but also a critical long-term goal 🦷🔍. This work adds to Mount Sinai’s growing contributions in precision Dermatology and underscores the potential of targeted immunomodulation for difficult mucocutaneous disease.

Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital

01/14/2026

👨‍⚕️✨ Get to know our Residents! 🏥💙

As and are underway, we are sharing why our residents chose the Icahn School of Medicine at Mount Sinai for their Dermatology training 🎓

This is Elisabeth George, MD!

📍 Hometown: Poquott, New York 🌊🗽
🎓 Medical School: Warren Alpert Medical School of Brown University
🎻 Fun Fact: I started playing violin at age three 🎼 and currently take adult ballet classes at Ballet Academy East 🩰✨
💬 Favorite Residency Memory: Traveling to Orlando with my co residents for the AAD 🛫🌴🤝
🔍 Plans After Residency: Mohs Fellowship 🧬✂️
💡 Why The Mount Sinai Hospital: The people and the amazing mentorship 🤍🤝

01/12/2026

Dr. Hongzhen Hu, Professor of Neuroscience and Dermatology and Scientific Director of the Mark Lebwohl Center for Neuroinflammation and Sensation, and colleagues report a compelling mechanistic framework for concussion biology 🧠🔬. Using the CHIMERA mouse model of mild traumatic brain injury, they map a clear sequence after head impact: immediate axonal varicosities, NMDA receptor linked microglial activation within hours, then cortical demyelination by about one day, with partial recovery over time.

📚 https://bit.ly/4pfs3u5

A key advance is the identification of TRPV4 as an actionable upstream control point for axon to glia mechanotransduction ⚡️.TRPV4 blockade (GSK2193874) given before impact markedly reduced axonal injury, microglial activation, demyelination, and several behavioral disturbances. Notably, dosing after impact still reduced axonal varicosities and demyelination and improved aspects of motor performance, supporting both prevention and mitigation strategies. Memantine, in contrast, reduced microglial activation and demyelination but did not prevent axonal varicosity formation, reinforcing that early axonal mechanosensation sits upstream of later glial pathology.

This work matters because TRP channels, including TRPV4, are central to neuroimmune signaling and sensation. Pinpointing a defined axon glia pathway that links mechanical stress to neuroinflammation strengthens the rationale for targeting shared sensation circuits relevant to itch and pain biology 🧬.

Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital

01/08/2026

👨‍⚕️✨ Get to know our Residents! 🏥💙

As and are underway, we are sharing why our residents chose the Icahn School of Medicine at Mount Sinai for their Dermatology training 🎓🧴

This is Jade Young, MD!🌟

📍 Hometown: Bend, Oregon 🌲🏔️
🎓 Medical School: Oregon Health and Science University
🎸 Fun Fact: I started rock climbing at age five and have loved it ever since 🧗‍♀️. It’s still my favorite way to spend time outdoors 🌞. I also love cooking 🍳, vintage shopping 🛍️, traveling ✈️, and a good karaoke night 🎤🎶.
💬 Favorite Residency Memory: Working alongside my research mentors as a resident, no longer as a student or fellow, was really special 🧠✨. It was the first time I truly appreciated how far I’d come, and how much more there is to learn 📈.
🩺 Plans After Residency: General Dermatology with interests in skin cancer, oncodermatology, and procedural dermatology 🔬✂️
💡 Why Mount Sinai: The Mount Sinai Hospital is a leader in innovation within Dermatology, and I knew I wanted to be part of that 🚀. There is incredible mentorship here for all career aspirations 🤝

01/07/2026

Dr. Patrick Brunner is part of the organizing committee of the World Congress of Cutaneous Lymphomas conference, helping to build excitement for their June 25-27 meeting in Montreal and advocating for the CTCL community.
Spotlight on Dr. Brunner:
🔗 https://www.facebook.com/photo?fbid=1157497256559194&set=a.406154268360167
Icahn School of Medicine at Mount Sinai

Spotlight on Patrick M. Brunner, MD

Dr. Patrick M. Brunner is an Associate Professor of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, NY, and Director of the Cutaneous Lymphoma Clinic in the Kimberly and Eric J. Waldman Department of Dermatology.
Dr. Brunner is a physician-scientist with a strong interest in skin immunology. His work focuses on chronic inflammatory skin diseases and primary cutaneous lymphomas, aiming to better understand how individual immune cells orchestrate skin inflammation in both benign and malignant conditions. He leads a translational research group dedicated to advancing immunobiologic insights and developing improved treatment strategies for patients with inflammatory skin disease and cutaneous lymphomas.

🏥 University Affiliation, City, Country: Icahn School of Medicine at Mount Sinai, New York, NY, USA
🧪 Area of focus in clinical practice and research: Chronic inflammatory skin diseases and cutaneous lymphomas
🔎 Looking forward to in the field of cutaneous lymphomas and at the 6th WCCL: Advancing translational discoveries that continue to reshape care for inflammatory and malignant skin diseases
💭 What are you passionate about in medicine or recreationally? The ongoing translational revolution in dermatology — from psoriasis and eczema to a growing range of inflammatory and malignant skin conditions — and the excitement of being a physician-scientist in this era
🏆 A short story or academic achievement you are proud of: Building and leading a translational research program focused on cutaneous immunobiology to improve patient-centered therapies
🌟 Secret to career success: Be passionate about what you do. Strategy matters, but loving your work is essential
🔗 Learn more: https://labs.icahn.mssm.edu/brunnerlab/

01/06/2026

This had success after 5 months of treatment.
As a college student she discovered patches of alopecia starting in February 2025. She and her parents were under significant emotional distress (even thinking about taking time away from school) because the hair loss was uncontrolled despite multiple steroid injections.
Dr. Guttman and her team started dupilumab weekly in July 2025 and now after only 5 months there is significant hair regrowth throughout.
At our Alopecia Center of Excellence, we offer some of the safest and effective options for both male and female pattern hair loss, including:
• Medications
• PRP (Platelet-Rich Plasma) therapy
• Laser treatments
• Hair transplantation
Our team not only specializes in these treatments — we've helped develop many of them. We are committed to providing our patients safe, effective and personalized care.

To make an appointment, email: alopecia@mountsinai.org.
Details: https://bit.ly/alopecia_MSDerm
Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

01/05/2026

A new case report from the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, in collaboration with colleagues in Rheumatology and Pathology at as well as Weill Cornell Medicine (Dr. Cynthia Magro), describes a rare and instructive presentation of methotrexate-associated primary cutaneous Epstein–Barr virus positive polymorphic B-cell lymphoproliferative disorder that ultimately evolved into angioimmunoblastic T-cell lymphoma 🧬🔬. The patient, a fifty-five-year-old woman with longstanding rheumatoid arthritis on methotrexate, developed a waxing and waning papulonodular eruption on the chest and neck, highlighting how the skin can serve as an early window into systemic immune dysregulation 🩺🧠. Careful clinicopathologic correlation revealed EBV positive, CD30 positive atypical B cells in the skin, with molecular studies later demonstrating that the same T-cell clone present in the cutaneous lesions was ultimately identified in nodal disease.

📚 https://bit.ly/4pa3n64

This report underscores several critical points for Dermatology and dermatopathology practice ✨. First, not all methotrexate-associated cutaneous lymphoproliferative disorders follow a benign or self-limited course after immunosuppression is withdrawn. While many EBV driven B-cell proliferations regress with cessation of methotrexate, this case illustrates that a subset may harbor an underlying clonal T-cell population that can evolve over time into an aggressive T-cell lymphoma ⚠️. Second, the histologic overlap between EBV positive polymorphic B-cell lymphoproliferative disorder and angioimmunoblastic T-cell lymphoma can be striking, emphasizing the importance of longitudinal sampling, immunophenotyping, and molecular analysis 🧪📊. Finally, this work reinforces the concept that chronic immune dysregulation, whether endogenous from autoimmune disease or iatrogenic from immunosuppressive therapy, can drive complex and dynamic lymphoid neoplasia.

We are proud of this multidisciplinary collaboration at Mount Sinai, which highlights the essential role of Dermatology in identifying early and atypical manifestations of systemic lymphoid disease, advancing diagnostic precision, and informing long-term patient monitoring and care 🏥💙.

The Mount Sinai Hospital

01/02/2026

Congratulations! Dr. Emma Guttman was honored as #5 in Dermatology worldwide,
2025 Highly Ranked Scholar — Prior Five Years, by ScholarGPS! 👏 🎉 🙌
This is in recognition of Dr. Guttman’s prolific publication record and high impact scholarly work which places her in the top 0.05% of scholars in Dermatology across the globe. Dr. Guttman was recognized as:
Highly Ranked Scholar— Lifetime Overall
# 6 Atopic Dermatitis
Highly Ranked Scholar— Prior Five Years
#2,168 Overall (All Fields)
#213 Medicine
#5 Dermatology
#2 Atopic dermatitis
#17 Allergy

Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

12/31/2025

👨‍⚕️✨ Get to know our Residents! 🏥💙

As and are underway, we are sharing why our residents chose the Icahn School of Medicine at Mount Sinai for their Dermatology training 🎓🧴

Meet Camille Rothenberg Lausell, MD, MS🌟
📍 Hometown: San Juan, Puerto Rico
🎓 Medical School: University of Puerto Rico School of Medicine
💬 Favorite Residency Memory: Meeting my co-residents for the first time 😊
💡 Why Mount Sinai: Outstanding mentorship 🧠, access to excellent patient care 🩺, and the opportunity to care for Spanish-speaking patients 🌎🗣️. I love being part of a program with so many opportunities 🚀✨

The Mount Sinai Hospital

12/29/2025

Dr. Mark Lebwohl and Dr. Alexandra Golant of Icahn School of Medicine at Mount Sinai are senior authors on a timely position paper in the Journal of Investigative Dermatology addressing systemic corticosteroid use in atopic dermatitis and the persistent gap between guidelines and real world practice 🧴📊. Despite longstanding recommendations discouraging routine or prolonged use, systemic corticosteroids remain widely prescribed in atopic dermatitis, often without a clear definition of what truly constitutes “short term” therapy. This paper confronts that ambiguity head on, synthesizing epidemiologic data, safety evidence, and expert consensus to propose a biologically grounded framework that prioritizes patient safety and modern, corticosteroid sparing care.

📚 https://bit.ly/4j9t3y9

Drawing on large population based studies, the authors highlight that even very brief systemic corticosteroid courses, often six days or less, are associated with meaningful risks including infection, venous thromboembolism, fracture, adrenal suppression, and rebound flaring 🚨. Importantly, the paper emphasizes that the assumption of safety with short term use is not supported by evidence. The authors propose a clear and actionable definition, any systemic corticosteroid exposure in atopic dermatitis should be considered a systemic therapy trial and should trigger timely transition to advanced systemic options rather than repeated cycling. This framework has major implications not only for clinical decision making, but also for payer policies and step therapy requirements that may inadvertently prolong harmful exposure.

Atopic dermatitis patients deserve treatments that are both effective and aligned with contemporary safety data 🔬. By clearly defining limits on systemic corticosteroid use and reframing even brief exposure as a systemic trial, this work supports earlier access to biologics and oral targeted therapies that offer sustained disease control. We are proud to see The Mount Sinai Hospital faculty leading evidence based efforts that challenge entrenched practice patterns and advance safer, more precise care for patients with inflammatory skin disease.

12/26/2025

This comprehensive review, led by Dr. Emma Guttman-Yassky from Icahn School of Medicine at Mount Sinai, examines rocatinlimab, a first in class therapy targeting the OX40 receptor to rebalance pathogenic T cells in atopic dermatitis. 🧬🧠 Atopic dermatitis remains a chronic, relapsing inflammatory disease driven by T cell imbalance, with many patients failing to achieve durable control despite biologics and JAK inhibitors. Rocatinlimab is designed to act upstream, directly targeting activated effector and memory T cells that sustain inflammation and disease chronicity. 🔬✨ Phase two b data demonstrate significant improvements in disease severity, pruritus, sleep disturbance, and quality of life by week sixteen, with responses continuing through week thirty six. Notably, many responders maintained clinical benefit for up to twenty weeks after treatment discontinuation, highlighting the potential for durable, disease modifying effects. ⏳🌿 These findings suggest a meaningful shift in how we may approach long term management of moderate to severe atopic dermatitis by addressing immune imbalance at its source rather than downstream cytokines alone.

📚 https://bit.ly/4qjb9vp

This work underscores the evolving paradigm in precision Dermatology, where targeting pathogenic T cell biology may allow for longer dosing intervals, sustained remission, and improved patient outcomes. By focusing on the mechanisms that drive chronic inflammation and memory T cell persistence, rocatinlimab represents a promising step toward redefining treatment goals in atopic dermatitis, moving beyond short term control toward durable disease modification. We are proud to see Mount Sinai Dermatology at the forefront of advancing translational immunology for patients with inflammatory skin disease. 🏥🔬🌍

The Mount Sinai Hospital

12/24/2025

🩺Investigators from the Icahn School of Medicine at Mount Sinai, including Dr. Jonas A. Adalsteinsson and Dr. Saakshi Khattri, report early clinical experience with deucravacitinib for cutaneous lupus erythematosus in the International Journal of Dermatology. 🧬✨ This clinical correspondence describes two patients with refractory cutaneous lupus erythematosus who showed meaningful improvement after treatment with deucravacitinib, an oral, allosteric tyrosine kinase two inhibitor currently approved for psoriasis. 🌿💊🧠 In a disease area with no FDA approved systemic therapies specifically for cutaneous lupus, these observations highlight a promising therapeutic direction grounded in immune pathway targeting.

📚 https://bit.ly/3Yx3EoD

In both cases, patients had longstanding, biopsy confirmed disease with limited or inadequate response to conventional therapies including antimalarials, systemic corticosteroids, methotrexate, and retinoids. Following initiation of deucravacitinib at 6 mg daily, improvement in inflammatory plaques was observed within weeks to months, with healing of lesions and residual post inflammatory pigmentary change, and no reported adverse events during follow up. 🔬📉🧪 Mechanistically, targeting TYK2 is particularly compelling in cutaneous lupus, given its central role in interferon signaling pathways known to drive disease activity. While limited by small sample size, this report adds to a growing body of evidence supporting TYK2 inhibition as a potential option for severe or treatment resistant cutaneous lupus. Together, this work reflects Mount Sinai’s ongoing leadership in translational and precision Dermatology, where thoughtful clinical observation informs future trials and expands therapeutic possibilities for patients with complex inflammatory skin disease. 🏛️🌍🔍